RESEARCH USE ONLY. ≥98% HPLC PURITY. SAME-DAY ORDER DISPATCH. TEMPERATURE-CONTROLLED STORAGE. FREE UK SHIPPING ON ORDERS £49.99+
Lynx Peptides

Animal & cell studies

Ipamorelin

Relative endocrine selectivity, pituitary adaptation and rat bone-size findings illuminate different parts of ipamorelin pharmacology.

Research summary

Ipamorelin, the first selective growth hormone secretagogue.

European journal of endocrinology 1998

Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH

Cell, rat and swine pharmacology

Ipamorelin stimulated growth-hormone release in rat pituitary cells and animal experiments. In swine comparisons, GHRP-2 and GHRP-6 raised ACTH and cortisol, while ipamorelin did not produce significant increases above the GHRH comparison. This is the basis for its relative selectivity under those conditions, rather than a guarantee of an identical hormonal profile in every model.

View on PubMed

Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.

Histology and histopathology 2002

Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G

Rat skeletal model

Prior ipamorelin exposure changed secretory-granule density and subsequent growth-hormone responses in pituitary cells from young female rats. The basal proportion of somatotrophs stayed similar across groups. This distinguishes adaptation in secretion and hormone content from a simple increase in the number of growth-hormone-producing cells.

View on PubMed

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.

The Journal of endocrinology 2000

Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO

Rat pharmacology model

Higher bone mineral content after ipamorelin in female rats reflected larger bones, not an increase in their intrinsic mineral density. Volumetric density and mineral concentration were unchanged after growth was accounted for. Distinguishing bone size from bone density is essential when interpreting these 12-week animal findings.

View on PubMed

Models studied

  • Growth-hormone secretagogue pharmacology
  • Pituitary somatotroph responses
  • Growth-hormone release in animal models
  • Skeletal research in rats

Key findings

  • Endocrine selectivity in context

    Relative endocrine selectivity arose from defined animal comparisons, with GH release distinguished from ACTH and cortisol responses.

  • Pituitary adaptation

    Pituitary adaptation involved granule content and secretion, while the basal somatotroph proportion remained similar.

  • Bone size versus mineral density

    Larger rat bones explained increased mineral content; intrinsic mineral density did not rise.

References

  1. Ipamorelin, the first selective growth hormone secretagogue.

    European journal of endocrinology 1998

    Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH

    PMID 9849822

    View on PubMed

  2. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.

    Histology and histopathology 2002

    Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G

    PMID 12168778

    View on PubMed

  3. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.

    The Journal of endocrinology 2000

    Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO

    PMID 10828840

    View on PubMed

For laboratory research use only. Content is provided for research reference and is not intended as medical or veterinary guidance.